Stay updated on Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial
Sign up to get notified when there's something new on the Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial page.

Latest updates to the Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page revision label was updated from v3.4.1 to v3.4.2. No substantive changes to study details are indicated.SummaryDifference0.0%

- Check20 days agoChange DetectedThe page now shows Revision: v3.4.1 and the previous Revision: v3.4.0 was removed, which appears to be a minor metadata update with no changes to study content or availability. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check27 days agoChange DetectedThe page now shows a glossary and includes updated metadata (Last Update Submitted that Met QC Criteria) and Revision: v3.4.0. The previous QC wording, older FEAR Act wording, and the prior revision (v3.3.4) have been removed.SummaryDifference0.1%

- Check42 days agoChange DetectedThe page's Revision label updated from v3.3.3 to v3.3.4, indicating a backend/site version change. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedA Locations section listing participating sites across the United States, Australia, Canada, and Poland was added, and location listings were revised (some entries removed).SummaryDifference2%

- Check91 days agoChange DetectedPubMed publications are now described as automatically populated from PubMed and may not all relate to the study. The revision label updated from v3.2.0 to v3.3.2.SummaryDifference0.4%

Stay in the know with updates to Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial page.